| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4200654 | F | Anticancer activity in patient with non-resectable locally advanced pancreatic cancer assessed as increase in 1 year survival at 400 mg/day, po co-administered with gemcitabine relative to gemcitabine alone | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 2. | ALA4200656 | B | Inhibition of uPA (unknown origin) | Homo sapiens | 2 | single protein format | Scientific Literature | ||
| 3. | ALA4614168 | A | Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 160 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay | Homo sapiens | 1 | assay format | Scientific Literature | ||
| 4. | ALA4614173 | A | Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 160 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay | Homo sapiens | 1 | assay format | Scientific Literature | ||
| 5. | ALA4614178 | A | Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 160 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay | Homo sapiens | 1 | assay format | Scientific Literature | ||
| 6. | ALA4614183 | A | Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 160 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay | Homo sapiens | 1 | assay format | Scientific Literature |
The page will load shortly, Thanks for your patience!